Wedbush upgraded shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL – Free Report) from an underperform rating to a neutral rating in a report issued on Monday, Marketbeat.com reports. The firm currently has $4.00 price target on the stock. Wedbush also issued estimates for Zentalis Pharmaceuticals’ Q3 2024 earnings at ($0.86) EPS, Q4 2024 earnings at ($0.87) EPS, FY2024 earnings at ($2.83) EPS, Q1 2025 earnings at ($0.91) EPS, Q2 2025 earnings at ($0.92) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.74) EPS, FY2025 earnings at ($3.25) EPS, FY2026 earnings at ($2.89) EPS, FY2027 earnings at ($2.19) EPS and FY2028 earnings at ($1.31) EPS.
Other research analysts also recently issued research reports about the stock. Morgan Stanley restated an equal weight rating and set a $8.00 price target (down previously from $38.00) on shares of Zentalis Pharmaceuticals in a research report on Tuesday, June 18th. Wells Fargo & Company lowered Zentalis Pharmaceuticals from an overweight rating to an equal weight rating and cut their price objective for the stock from $29.00 to $9.00 in a research note on Tuesday, June 18th. Oppenheimer decreased their target price on Zentalis Pharmaceuticals from $50.00 to $25.00 and set an outperform rating on the stock in a research report on Tuesday, June 18th. HC Wainwright reaffirmed a buy rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a research note on Monday. Finally, UBS Group downgraded Zentalis Pharmaceuticals from a buy rating to a neutral rating and reduced their price objective for the company from $28.00 to $5.00 in a research note on Thursday, June 20th. Seven research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of Hold and a consensus target price of $11.33.
View Our Latest Research Report on ZNTL
Zentalis Pharmaceuticals Price Performance
Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report) last issued its quarterly earnings results on Friday, August 9th. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.40). During the same period in the prior year, the firm earned ($1.85) EPS. On average, equities research analysts anticipate that Zentalis Pharmaceuticals will post -2.72 EPS for the current fiscal year.
Insider Buying and Selling
In other news, CFO Cam Gallagher sold 9,597 shares of Zentalis Pharmaceuticals stock in a transaction on Friday, May 31st. The stock was sold at an average price of $11.98, for a total transaction of $114,972.06. Following the transaction, the chief financial officer now owns 633,680 shares in the company, valued at approximately $7,591,486.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 6.10% of the stock is currently owned by company insiders.
Institutional Trading of Zentalis Pharmaceuticals
A number of hedge funds and other institutional investors have recently made changes to their positions in ZNTL. Quest Partners LLC acquired a new stake in shares of Zentalis Pharmaceuticals during the 4th quarter worth about $38,000. Anfield Capital Management LLC acquired a new stake in shares of Zentalis Pharmaceuticals during the second quarter valued at about $40,000. Tower Research Capital LLC TRC increased its position in shares of Zentalis Pharmaceuticals by 252.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,615 shares of the company’s stock valued at $55,000 after acquiring an additional 2,589 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Zentalis Pharmaceuticals in the 2nd quarter valued at approximately $58,000. Finally, American Century Companies Inc. acquired a new position in shares of Zentalis Pharmaceuticals in the 2nd quarter worth approximately $95,000.
Zentalis Pharmaceuticals Company Profile
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.
Recommended Stories
- Five stocks we like better than Zentalis Pharmaceuticals
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- 3 Warren Buffett Stocks to Buy Now
- Jeff Brown’s Exegesis AI Stock Picks
- 10 Best Airline Stocks to Buy
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.